The Financial Times reports that Novartis received a binding offer from Siemens Healthineers to acquire its molecular imaging business.
According to the report, Siemens Healthineers plans to pay approximately $224 million to buy the unit. It’s acquiring the diagnostic arm of Advanced Accelerator Operations, owned by Novartis. That business provides Fluorine-18 positron emission tomography, or PET scans.
Reuters said Novartis declined to confirm the value of the deal. That report said Novartis plans for Siemens Healthineers to remain a partner in its radioligand therapy (RLT) business. Reuters also said the companies expect the transaction to close in the fourth quarter of 2024.
Novartis originally bought the Advanced Accelerator Applications business for $3.9 billion in 2017.
